Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer

• Status: Unknown status
• Trial end date: 2018-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Objectives:

To evaluate the safety and effectiveness of cell therapy using precision cells to treat Advanced Lung Cancer.

Eligibility:

Individuals greater than or equal to 18 years of age and less than or equal to 65 years of age who have been diagnosed with Advanced Lung Cancer.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai International Medical Center

Criteria

Inclusion Criteria:

• Age 18~65 years old, male or female;

• Life expectancy≥6 months;

• ECOG score: 0-3;

• Advanced Malignancies (lung cancer) were diagnosed by pathological or clinical physicians;

• Enough venous channel, no other contraindications to the separation and collection of white blood cells;

• Laboratory examination: white blood cell≥3 x 10*9/L, blood platelet count≥60 x 10*/L,hemoglobin≥85g/L; lymphocyte count≥15%, total bilirubin≤100 mol/L; ALT and AST less than five times of the normal level; serum creatinine less than 1.5 times of the normal level;

• Signed informed consent;

• Women of child-bearing age must have evidence of negative pregnancy test and be willing to practice birth control after 2 weeks following the cells transfusion.

Exclusion Criteria:

• Expected Overall survival < 6 months;

• Patients with uncontrolled hypertension (>160/95mmHg), unstable coronary disease (uncontrolled arrhythmias, unstable angina, decompensated congestive heart failure (> Class II, NYHA), or myocardial infarction within 6 months;

• Other serious diseases: nervous, mental disorders, immune regulatory diseases, metabolic diseases, infectious diseases, etc;

• Other drugs, or other biological treatment,chemotherapy or radiotherapy are performed within a month;

• Unable or unwilling to provide informed consent, or fail to comply with the test requirements.